Asthma is more dangerous than many people realize. An estimated 10 Americans die everyday from asthma, and the disease leads to around 439,000 hospitalizations and 1.3 million emergency room trips each year.
First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
Researchers evaluated immune responses to COVID-19 BNT162b2 mRNA vaccinations among Indigenous Australian First Nations (FN) individuals by comorbidity and ethnicity.